Melyssa specialises in developing chelator systems for use in radiopharmaceuticals
Melyssa's research focuses primarily on the design of ligands for radionuclides that have a potential for use in targeted alpha therapy. This work includes the initial design and synthesis of these ligands, investigation of the properties of the non-radioactive metal complexes and developing the radiochemistry for the corresponding radiolabelled compounds. Melyssa is from Melbourne, where she completed her PhD at Monash University in 2024. Her PhD candidature included visiting research trips to the Centre for Advanced Imaging at the University of Queensland and the Institute of Radiopharmaceutical Cancer Research at Helmholtz-Zentrum Dresden-Rossendorf in Dresden, Germany. She has now joined the Paterson Group as a Postdoctural researcher working on developing and optimising the radiochemistry of both established and novel chelators with therapeutic radionuclides.
Key Publications
M. L. Grieve, P. R. W. J. Davey, C. M. Forsyth and B. M. Paterson, The Synthesis of a Bis(thiosemicarbazone) Macrocyclic Ligand and the Mn(II), Co(II), Zn(II) and 68Ga(III) Complexes, Molecules, 2021, 26, 3646.
M. L. Grieve and B. M. Paterson, The Evolving Coordination Chemistry of Radiometals for Targeted Alpha Therapy, Aus. J. Chem., 2021, 75, 65-88.